IL-10 Knockout Colitis Model

Creative Bioarray has successfully developed the IL-10 Knockout Colitis Model, a highly relevant and extensively validated animal model that spontaneously develops inflammatory bowel disease (IBD). This model is characterized by abnormal weight gain or loss, decreased survival rates, heightened levels of inflammatory cytokines, pronounced intestinal inflammation, and distinct abnormalities in intestinal phenotypes. This model serves as an invaluable tool for researchers, enabling them to closely mimic human IBD conditions and thereby accurately evaluate the potential of new therapeutic agents.

IL-10 is crucial in the susceptibility to IBD, especially in patients with very early-onset IBD, where mutations in IL10 and its receptor are commonly found. The IL10 knockout mouse model, which mirrors human IBD symptoms, is widely used in research. This model features a Th1/Th17 immune response, epithelial hyperplasia, and other inflammatory markers, and it develops colitis spontaneously due to IL-23 and Th1-like inflammation, influenced by genetic background. Under specific pathogen-free (SPF) conditions, BALB/c IL10 KO mice exhibit early, severe disease with minimal variation, closely replicating human chronic colitis. These mice are essential for understanding IBD mechanisms and screening new drugs, proving invaluable in IBD research.

Our IL-10 Knockout Colitis Model

Animal Species

• BALB/c-IL-10 knockout mouse

Endpoints

• Body weight
• DAI score
• Colon weight
• Colon length
• qPCR or Western blot
• Histology analysis
• Other customized endpoints according to your specific needs

Example Data

Fig. 1 Effect of Epac-2 on colitis in Il-10^-/- mice. (A) The DAI scores of mice in the WT group, Il-10^-/- group, Me-cAMP group and HJC-0350 group. (B) Haematoxylin and eosin (H&E) staining revealed the histological manifestations of colonic tissues in each group after 4 weeks of treatment. (C) The inflammatory scores revealed the values of intestinal tissues in each group after treatment. (D) The colon lengths of mice in each group were measured and recorded after treatment completion. (E-G) The protein levels of TNF-α, IL-1β and IL-17A in colons from mice in each group. (H-J) The mRNA levels of cytokines in colons from mice in each group. (Song et al. 2022)

Quotation and Ordering

Creative Bioarray is recognized as a premier CRO for preclinical drug development. We assist in selecting the most validated and dependable models for testing your compounds. Furthermore, we collaborate with our clients to create new animal models that are customized to meet their unique pharmaceutical screening and evaluation needs. If you are interested in our services, please do not hesitate to contact us at any time or submit an inquiry to us directly.

Reference

1. Song, X., et al. Epac-2 ameliorates spontaneous colitis in Il-10^-/- mice by protecting the intestinal barrier and suppressing NF-κB/MAPK signaling. Journal of Cellular and Molecular Medicine, 2022, 26(1): 216-227.

For research use only. Not for any other purpose.